Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is reporting second quarter earnings results on Monday 10th August 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.17 per share.
For the full year, analysts predict revenues of $ 24.69 million, while looking forward to loss of $ 0.7 per share.
Previous Quarter Performance
Inovio Pharmaceuticals, Inc. unwinded loss for the first quarter of $ 0.26 per share, from the revenue of $ 1.33 million. The quarterly revenues down 53.00 percent compared with the same quarter last year. Street analysts expected Inovio Pharmaceuticals, Inc. to report loss of $ 0.22 per share on revenue of $ 1.91 million for the first quarter. The bottom line results missed street analysts by $ 0.04 or 18.18 percent, at the same time, top line results fell short of analysts by $ 0.58 million or 30.37 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Inovio Pharmaceuticals, Inc.
Stock Performance
According to the previous trading day, closing price of INO was $ 20.22, representing a 953.13 % increase from the 52 week low of $ 1.92 and a 40.16 % decrease over the 52 week high of $ 33.79.
The company has a market capital of $ 3.20 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”INO” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 29th June 2020, downgraded by HC Wainwright to Neutral from Buy rating.
Conference Call
Inovio Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.inovio.com
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus.
